Diabetogenic T-cell clones recognize an altered peptide of chromogranin A

Diabetes. 2012 Dec;61(12):3239-46. doi: 10.2337/db12-0112. Epub 2012 Aug 21.

Abstract

Chromogranin A (ChgA) has been identified as the antigen target for three NOD-derived, diabetogenic CD4 T-cell clones, including the well-known BDC-2.5. These T-cell clones respond weakly to the peptide WE14, a naturally occurring proteolytic cleavage product from ChgA. We show here that WE14 can be converted into a highly antigenic T-cell epitope through treatment with the enzyme transglutaminase (TGase). The WE14 responses of three NOD-derived CD4 T-cell clones, each with different T-cell receptors (TCRs), and of T cells from BDC-2.5 TCR transgenic mice are increased after TGase conversion of the peptide. Primary CD4 T cells isolated from NOD mice also respond to high concentrations of WE14 and significantly lower concentrations of TGase-treated WE14. We hypothesize that posttranslational modification plays a critical role in the generation of T-cell epitopes in type 1 diabetes.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • CD4-Positive T-Lymphocytes / immunology
  • CD4-Positive T-Lymphocytes / metabolism
  • Cell Proliferation
  • Cells, Cultured
  • Chromatography, Gel
  • Chromogranin A / immunology*
  • Flow Cytometry
  • Mice
  • Mice, Inbred NOD
  • Mice, Transgenic
  • Peptides / immunology*
  • Receptors, Antigen, T-Cell / immunology*
  • Transglutaminases / metabolism

Substances

  • Chromogranin A
  • Peptides
  • Receptors, Antigen, T-Cell
  • Transglutaminases